Survival Bump in Unfit NSCLC With First-Line Immunotherapy
(MedPage Today) -- PARIS -- Treatment with a PD-L1 inhibitor held a survival advantage over single-agent chemotherapy for unfit non-small cell lung cancer (NSCLC) patients ineligible for platinum doublets, findings from the IPSOS trial showed...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer